Literature DB >> 6137769

Acetylcholinesterase and ATPases in motor neuron degenerative diseases.

C G Rasool, W G Bradley, B Connolly, J K Baruah.   

Abstract

Acetylcholinesterase (AChE) activity was measured in the presence of the specific inhibitor of pseudocholinesterase, iso-OMPA, in plasma from patients with amyotrophic lateral sclerosis (ALS), progressive muscular atrophy (PMA), neuromuscular disease controls, and normal controls. Both AChE and Na-K ATPase activities were measured in erythrocyte ghost membranes from ALS and normal controls. Activities of erythrocyte ghost AChE and Na-K ATPase did not differ between ALS and control patients, suggesting that erythrocyte membranes were normal in ALS. However, the activity of plasma AChE in patients with ALS and PMA was increased significantly over plasma activity in disease controls and normal controls. In addition, in an animal model of human PMA, the Wobbler mouse, plasma AChE activity was increased significantly over littermate controls. The explanation for the increase in plasma acetylcholinesterase was not clear; however, a number of potentially useful clinical points followed from this study. First, there was no relationship between a specific subtype of motor neuron disease and the level of AChE activity. Second, AChE activity appeared to vary directly with the duration of PMA but not with the severity of PMA. This did not correlate with either the duration or severity of ALS. Last, plasma AChE activity was normal in about 30% of patients who had motor neuron disease; therefore, AChE assay had limited use in the diagnosis of ALS or PMA.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6137769     DOI: 10.1002/mus.880060606

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  4 in total

Review 1.  Neuromuscular Junction Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Sagar Verma; Shiffali Khurana; Abhishek Vats; Bandana Sahu; Nirmal Kumar Ganguly; Pradip Chakraborti; Mandaville Gourie-Devi; Vibha Taneja
Journal:  Mol Neurobiol       Date:  2022-01-08       Impact factor: 5.590

2.  Monoclonal antibodies to human brain acetylcholinesterase: properties and applications.

Authors:  Z Rakonczay; S Brimijoin
Journal:  Cell Mol Neurobiol       Date:  1988-03       Impact factor: 5.046

Review 3.  Neuromuscular Junction Impairment in Amyotrophic Lateral Sclerosis: Reassessing the Role of Acetylcholinesterase.

Authors:  Maria-Letizia Campanari; María-Salud García-Ayllón; Sorana Ciura; Javier Sáez-Valero; Edor Kabashi
Journal:  Front Mol Neurosci       Date:  2016-12-27       Impact factor: 5.639

Review 4.  Amyotrophic lateral sclerosis as a protein level, non-genomic disease: Therapy with S2RM exosome released molecules.

Authors:  Greg Maguire
Journal:  World J Stem Cells       Date:  2017-11-26       Impact factor: 5.326

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.